NexPoint Aims to Prevent Paratek Takeover Deal
Investor claims agreement not suitable for shareholders.
NexPoint, an investor of Paratek Pharmaceuticals, revealed considerations to vote against the biopharma’s takeover by Gurnet Point Capital. NexPoint, which reportedly owns 12 percent of Paratek stock, believes that the sale could be detrimental to current stockholders. Reportedly, the firm is waiting for additional materials to be filed before making a final decision.
In a press release responding to NexPoint, Paratek stated, “Paratek appreciates receiving constructive feedback from its stockholders and as such, has actively engaged with NexPoint over the past several months. However, Paratek’s board of directors respectfully disagrees with NexPoint’s characterizations contained in its letter.” Under the deal, Paratek is expected to be taken private for approximately $462 million.
References: Paratek investor NexPoint warns it may vote against takeover deal. Seeking Alpha. June 27, 2023. Accessed June 30, 2023. https://seekingalpha.com/news/3983281-paratek-investor-nexpoint-warns-it-may-vote-against-takeover-deal?open_reset_password=true&origin=confirm_registration&utm_campaign=%7Cconfirmation_link_registration&utm_medium=email&utm_source=seeking_alpha
Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter. GlobeNewswire. June 27, 2023. Accessed June 30, 2023. https://www.globenewswire.com/news-release/2023/06/27/2695623/33636/en/Paratek-Pharmaceuticals-Acknowledges-Receipt-of-NexPoint-Letter.html
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
